BACKGROUND: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be life-threatening, and specific antiviral drugs are currently not available. However, first studies indicated that convalescent plasma treatment might improve the clinical outcome of coronavirus disease 2019 (COVID-19) patients. STUDY DESIGN AND METHODS: In the current study, we investigated the efficacy of convalescent plasma treatment in eight COVID-19 patients. All the patients were critically ill, and seven of them were SARS-CoV-2 RNA-positive when starting treatment. SARS-CoV-2-specific antibodies were determined by an enzyme-linked immunosorbent assay detecting immunoglobulin G (IgG) antibodies against the S1 protein (Euroimmun), and the neutralizing titers were determined with a cell-culture-based neutralization assay. Plasma treatment started between 4 and 23 days after the onset of symptoms. The patients were usually treated by three plasma units, each containing 200-280 ml, which was applied at day 1, 3, and 5. RESULTS: Donor sera had on average lower IgG antibody ratios and neutralizing titers than the COVID-19 patients before the onset of treatment (median ratio of 5.8 and neutralizing titer of 1:320 vs. 7.5 and 1:640, respectively). Nevertheless, we observed an increase of antibody ratios in seven and of neutralizing titers in five patients after treatment; which did, however, not correlate with patient survival. Plasma treatment was effective in three patients, but five deceased despite treatment. Patients who deceased had a later treatment onset than survivors and finally died from multiple organ failure. CONCLUSION: Our data indicate that the efficacy of convalescent plasma treatment of critically ill COVID-19 patients who already had developed strong antiviral immune responses and organ complications is limited.
BACKGROUND:Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be life-threatening, and specific antiviral drugs are currently not available. However, first studies indicated that convalescent plasma treatment might improve the clinical outcome of coronavirus disease 2019 (COVID-19) patients. STUDY DESIGN AND METHODS: In the current study, we investigated the efficacy of convalescent plasma treatment in eight COVID-19patients. All the patients were critically ill, and seven of them were SARS-CoV-2 RNA-positive when starting treatment. SARS-CoV-2-specific antibodies were determined by an enzyme-linked immunosorbent assay detecting immunoglobulin G (IgG) antibodies against the S1 protein (Euroimmun), and the neutralizing titers were determined with a cell-culture-based neutralization assay. Plasma treatment started between 4 and 23 days after the onset of symptoms. The patients were usually treated by three plasma units, each containing 200-280 ml, which was applied at day 1, 3, and 5. RESULTS: Donor sera had on average lower IgG antibody ratios and neutralizing titers than the COVID-19patients before the onset of treatment (median ratio of 5.8 and neutralizing titer of 1:320 vs. 7.5 and 1:640, respectively). Nevertheless, we observed an increase of antibody ratios in seven and of neutralizing titers in five patients after treatment; which did, however, not correlate with patient survival. Plasma treatment was effective in three patients, but five deceased despite treatment. Patients who deceased had a later treatment onset than survivors and finally died from multiple organ failure. CONCLUSION: Our data indicate that the efficacy of convalescent plasma treatment of critically illCOVID-19patients who already had developed strong antiviral immune responses and organ complications is limited.
Authors: Michael Jahn; Johannes Korth; Oliver Dorsch; Olympia Evdoxia Anastasiou; Adalbert Krawczyk; Leonie Brochhagen; Lukas van de Sand; Burkhard Sorge-Hädicke; Bartosz Tyczynski; Oliver Witzke; Ulf Dittmer; Sebastian Dolff; Benjamin Wilde; Andreas Kribben Journal: Vaccines (Basel) Date: 2022-02-18
Authors: Korbinian Wünsch; Olympia E Anastasiou; Mira Alt; Leonie Brochhagen; Maxim Cherneha; Laura Thümmler; Lukas van Baal; Rabea J Madel; Monika Lindemann; Christian Taube; Oliver Witzke; Hana Rohn; Adalbert Krawczyk; Sarah Jansen Journal: Viruses Date: 2022-04-01 Impact factor: 5.048
Authors: Jiazheng Guo; Jun Zhang; Peng Du; Jiansheng Lu; Lei Chen; Ying Huang; Yunzhou Yu; Qing Xie; Rong Wang; Zhixin Yang Journal: J Med Virol Date: 2022-05-07 Impact factor: 20.693
Authors: Ingvild Birschmann; Katharina von Bargen; Michelle Teune; Christian Flottmann; Franziska Knüttgen; Cornelius Knabbe Journal: Health Sci Rep Date: 2022-08-09